Organization: Chronogen Inc

Chronogen finalizes licensing deal with McGill

Montreal-based Chronogen Inc has secured an exclusive worldwide licence from McGill Univ for screening assays for targets and drugs used in the treatment and prevention of lipid disorder linked to atherosclerosis. The licensed technology, which expands Chronogen’s IP portfolio in the field of aging and age-related diseases, is based on discoveries made by Dr Siegfried…